Liposomal doxorubicin, cyclophosphamide, and etoposide and antiretroviral therapy for patients with AIDS-related lymphoma: A pilot study

Oncologist

Volumn 11, Issue 6, 2006, Pages 666-673

  Combs, Sara ^a   Neil, Nancy ^b,c   Aboulafia, David M ^a,d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Ovation Research Group   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

Antiretroviral therapy; Chemotherapy; HIV AIDS; Non Hodgkin's lymphoma

Indexed keywords

ANTIRETROVIRUS AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOMA; MALE; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD4 LYMPHOCYTE COUNT; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG CARRIERS; ETOPOSIDE; FEMALE; HUMANS; LIPOSOMES; LYMPHOMA, AIDS-RELATED; MALE; MIDDLE AGED; PILOT PROJECTS; SURVIVAL RATE; VIRAL LOAD;

EID: 33745673791     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-6-666     Document Type: Article

References (36)

1. Beral V, Peterman T, Berkelman R et al. AIDS-associated non-Hodgkin lymphoma. Lancet 1991;337:805-809.
2. Spina M, Vaccher E, Nasti G et al. Human immunodeficiency virus-associated Hodgkin's disease. Semin Oncol 2000;27:480-488.
3. Clifford GM, Polesel J, Rickenbach M et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005;97:425-432.
4. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000;92:1823-1830.
5. Kirk O, Pedersen C, Cozzi-Lepri A et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001;98:3406-3412.
6. Bonnet F, Lewden C, May T et al. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer 2004;101:317-324.
7. Berretta M, Cinelli R, Martellotta F et al. Therapeutic approaches to AIDS-related malignancies. Oncogene 2003;22:6646-6659.
8. Gisselbrecht C, Oksenhendler E, Tirelli U et al. Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. French-Italian Cooperative Group. Am J Med 1993;95:188-196.
9. Kaplan LD, Abrams DI, Feigal E et al. AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA 1989;261:719-724.
10. Levine AM. Acquired immunodeficiency syndrome-related lymphoma: clinical aspects. Semin Oncol 2000;27:442-453.
11. Kaplan LD, Straus DJ, Testa MA et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997;336:1641-1648.
12. Sparano JA, Wiernik PH, Strack M et al. Infusional cyclophosphamide, doxorubicin, and etoposide in human immunodeficiency virus- and human T-cell leukemia virus type I-related non-Hodgkin's lymphoma: a highly active regimen. Blood 1993;81:2810-2815.
13. Simonelli C, Zanussi S, Cinelli R et al. Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma. Clin Infect Dis 2003;37:820-827.
14. Little RF, Pittaluga S, Grant N et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003;101:4653-4659.
15. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996;125:47-58.
16. Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 1992;52:891-896.
17. Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001;19:424-436.
18. Jones RL, Berry GJ, Rubens RD et al. Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin. Lancet Oncol 2004;5:575-577.
19. Northfelt DW, Dezube BJ, Thommes JA et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998;16:2445-2451.
20. Markman M, Gordon AN, McGuire WP et al. Liposomal anthracycline treatment for ovarian cancer. Semin Oncol 2004;31(suppl 13):91-105.
21. Robert NJ, Vogel CL, Henderson IC et al. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Semin Oncol 2004;31(suppl 13):106-146.
22. Levine AM, Tulpule A, Espina B et al. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. J Clin Oncol 2004;22:2662-2670.
23. Carbone PP, Kaplan HS, Musshoff K et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1861.
24. Kaplan LD, Scadden DT. No benefit from rituximab in a randomized phase III trial of CHOP with or without rituximab for patients with HIVassociated non-Hodgkin's lymphoma: AIDS Malignancies Consortium Study 010. 2003 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 3, 2003.
25. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
27. Straus DJ, Huang J, Testa MA et al. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142 - low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases. J Clin Oncol 1998;16:3601-3606.
28. Rossi G, Donisi A, Casari S et al. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma. Cancer 1999;86:2391-2397.
29. Ratner L, Lee J, Tang S et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001;19:2171-2178.
30. Antinori A, Cingolani A, Alba L et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001;15:1483-1491.
31. de Jonge ME, Huitema AD, van Dam SM, et al. Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes. Anticancer Drugs 2005;16:331-336.
32. Anthracyclines in 2004. A Compendium of Current Clinical Data on the Use of Anthracyclines for the Treatment of Hematologic and Solid Malignancies. In: PeerView in Focus. Balducci L and Gabizon AA, eds. www. peerviewpress.com, 2005:7-52.
33. Spina M, Jaeger U, Sparano JA et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood 2005;105:1891-1897.
34. Bower M, McCall-Peat N, Ryan N et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 2004;104:2943-2946.
35. Kaplan LD, Lee JY, Ambinder RF et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin's lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005;106:1538-1543.
36. Sparano JA, Weller E, Nazeer T et al. Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493). Blood 2002;100:1634-1640.